BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...hired Stella Vnook as its first CEO. She was VP, managed markets and trade, at Assertio Therapeutics Inc....
BioCentury | Aug 26, 2019
Company News

FibroGen’s Neff passes away

...the company seeks a permanent successor. Schoeneck previously served as CEO of Depomed Inc., now Assertio Therapeutics Inc....
BioCentury | Aug 2, 2019
Finance

Earnings on deck

...$0.57 2% Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) 8/7 During (A) $0.57 $0.78 -27% Assertio Therapeutics Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...Post $0.47 $0.49 -4% H. Lundbeck A/S (CSE:LUN) 5/8 During DKK 4.55 DKK 6.03 -25% Assertio Therapeutics Inc....
BioCentury | Feb 22, 2019
Clinical News

FDA issues handful of new PDUFA dates

...infectious; musculoskeletal; ophthalmic Mark Zipkin entrectinib (RG6268, rxdx-101) lefamulin (BC-3781) Polatuzumab vedotin (DCDS4501A, RG7596) upadacitinib (ABT-494) Xipere, Zuprata (CLS-1001, CLS-TA, CLS 1001) Assertio Therapeutics Inc. Clearside...
BioCentury | Feb 20, 2019
Company News

Management tracks: Allergan, Arix, Quest, SurModics

...CMC at AveXis Inc., which Novartis AG (NYSE:NVS) acquired. Moretti was SVP and CFO at Assertio Therapeutics Inc....
BioCentury | Feb 19, 2019
Company News

FDA issues handful of new PDUFA dates

...tyrosine kinase; Trk - Neurotrophic tyrosine kinase receptor Mark Zipkin entrectinib (RG6268, rxdx-101) lefamulin (BC-3781) Polatuzumab vedotin (DCDS4501A, RG7596) upadacitinib (ABT-494) Assertio Therapeutics Inc. Genentech...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...May. BioDelivery also expanded President Scott Plesha's role to include chief commercial officer. Pain company Assertio Therapeutics Inc....
BioCentury | Dec 8, 2017
Company News

Collegium gets U.S. commercial rights to Nucynta from Depomed

...norepinephrine reuptake inhibitor. Depomed will receive $10 million up front, a cash payment equal to Depomed's...
...the time of close and an annual license fee of $135 million for four years. Depomed...
...on all sales after four years. The companies expect the deal to close in January. Depomed...
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

...hired Gregory Bates as SVP of regulatory affairs. He was VP of regulatory affairs at Depomed...
Items per page:
1 - 10 of 412
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...hired Stella Vnook as its first CEO. She was VP, managed markets and trade, at Assertio Therapeutics Inc....
BioCentury | Aug 26, 2019
Company News

FibroGen’s Neff passes away

...the company seeks a permanent successor. Schoeneck previously served as CEO of Depomed Inc., now Assertio Therapeutics Inc....
BioCentury | Aug 2, 2019
Finance

Earnings on deck

...$0.57 2% Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) 8/7 During (A) $0.57 $0.78 -27% Assertio Therapeutics Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...Post $0.47 $0.49 -4% H. Lundbeck A/S (CSE:LUN) 5/8 During DKK 4.55 DKK 6.03 -25% Assertio Therapeutics Inc....
BioCentury | Feb 22, 2019
Clinical News

FDA issues handful of new PDUFA dates

...infectious; musculoskeletal; ophthalmic Mark Zipkin entrectinib (RG6268, rxdx-101) lefamulin (BC-3781) Polatuzumab vedotin (DCDS4501A, RG7596) upadacitinib (ABT-494) Xipere, Zuprata (CLS-1001, CLS-TA, CLS 1001) Assertio Therapeutics Inc. Clearside...
BioCentury | Feb 20, 2019
Company News

Management tracks: Allergan, Arix, Quest, SurModics

...CMC at AveXis Inc., which Novartis AG (NYSE:NVS) acquired. Moretti was SVP and CFO at Assertio Therapeutics Inc....
BioCentury | Feb 19, 2019
Company News

FDA issues handful of new PDUFA dates

...tyrosine kinase; Trk - Neurotrophic tyrosine kinase receptor Mark Zipkin entrectinib (RG6268, rxdx-101) lefamulin (BC-3781) Polatuzumab vedotin (DCDS4501A, RG7596) upadacitinib (ABT-494) Assertio Therapeutics Inc. Genentech...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...May. BioDelivery also expanded President Scott Plesha's role to include chief commercial officer. Pain company Assertio Therapeutics Inc....
BioCentury | Dec 8, 2017
Company News

Collegium gets U.S. commercial rights to Nucynta from Depomed

...norepinephrine reuptake inhibitor. Depomed will receive $10 million up front, a cash payment equal to Depomed's...
...the time of close and an annual license fee of $135 million for four years. Depomed...
...on all sales after four years. The companies expect the deal to close in January. Depomed...
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

...hired Gregory Bates as SVP of regulatory affairs. He was VP of regulatory affairs at Depomed...
Items per page:
1 - 10 of 412